

David M Faleck

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6341386/publications.pdf>

Version: 2024-02-01

24
papers

1,063
citations

623734

14
h-index

752698

20
g-index

24
all docs

24
docs citations

24
times ranked

1550
citing authors

#	ARTICLE	IF	CITATIONS
1	Enterocolitis due to immune checkpoint inhibitors: a systematic review. <i>Gut</i> , 2018, 67, 2056-2067.	12.1	179
2	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 576-583.	1.6	135
3	Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. <i>American Journal of Gastroenterology</i> , 2018, 113, 1345.	0.4	119
4	Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 873-879.	3.7	76
5	Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1169-1186.	1.9	63
6	Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1533-1540.e2.	4.4	60
7	Proton Pump Inhibitors Do Not Increase Risk for <i>Clostridium difficile</i> Infection in the Intensive Care Unit. <i>American Journal of Gastroenterology</i> , 2016, 111, 1641-1648.	0.4	54
8	Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2200-2208.	7.0	51
9	Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2461-2467.	1.9	50
10	Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1759-1764.	1.1	49
11	Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. , 2021, 9, e003277.		49
12	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2952-2961.e8.	4.4	48
13	Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2497-2505.e1.	4.4	44
14	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 126-135.	4.4	32
15	Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 238-245.e4.	4.4	17
16	Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1854-1861.	1.9	11
17	Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events. <i>Clinical Cancer Research</i> , 2022, 28, 1250-1257.	7.0	11
18	Contribution of the Skin-Gut Axis to Immune-Related Adverse Events with Multi-System Involvement. <i>Cancers</i> , 2022, 14, 2995.	3.7	5

#	ARTICLE	IF	CITATIONS
19	Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series. <i>Oncologist</i> , 2022, 27, e350-e352.	3.7	4
20	Endoscopic submucosal dissection for colorectal dysplasia in inflammatory bowel disease: a US multicenter study. <i>Endoscopy International Open</i> , 2022, 10, E354-E360.	1.8	4
21	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1646-1647.	4.4	1
22	Reply to Y. Inagaki et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 1749-1750.	1.6	1
23	Response to Goyal and Katner. <i>American Journal of Gastroenterology</i> , 2017, 112, 806.	0.4	0
24	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 469.	4.4	0